Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Sarcoma 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 9Fallopian Tube Neoplasms 8Neoplasms 6Prostatic Neoplasms 5Carcinoma, Ovarian Epithelial 5Recurrence 3Pancreatic Neoplasms 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Metastatic Castration Resistant Prostate Cancer 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Sarcoma 1Primary Myelofibrosis 1Pathologic Complete Response 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1

Interventions

pembrolizumab 40Gemcitabine 37Cisplatin 28Carboplatin 17enfortumab vedotin 15Nivolumab 15Mitomycin 14atezolizumab 13avelumab 12Docetaxel 10vinflunine 95-aminolevulinic acid hexyl ester 9apaziquone 8Paclitaxel 8BCG Vaccine 7durvalumab 6Fluorouracil 6Cystectomy 6sacituzumab govitecan 4Surgical Procedures, Operative 4Drug Therapy 4vofatamab 3valrubicin 3tisotumab vedotin 3erdafitinib 3cemiplimab 3belinostat 3Therapeutic Uses 3Ramucirumab 3Cystoscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Urinary Bladder Neoplasms × rucaparib × Clear all
NCT04171700 2023-10-02

LODESTAR

pharmaand GmbH

Phase 2 Terminated
83 enrolled 16 charts
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinosarcoma, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Leiomyosarcoma, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03397394 2023-06-09

ATLAS

pharmaand GmbH

Phase 2 Terminated
97 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡